ATX — Amplia Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$16.49m
- AU$13.07m
- AU$1.15m
- 16
- 39
- 28
- 17
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.05 | 0.034 | 1.53 | 1.98 | 1.15 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.94 | 2.26 | 3.82 | 5.63 | 7.48 |
Operating Profit | -1.89 | -2.22 | -2.28 | -3.64 | -6.33 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.87 | -2.22 | -2.28 | -3.64 | -6.24 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.87 | -2.22 | -2.28 | -3.64 | -6.24 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.87 | -2.22 | -2.28 | -3.64 | -6.24 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.87 | -2.22 | -2.28 | -3.64 | -6.24 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.043 | -0.042 | -0.024 | -0.025 | -0.032 |